StairMed Raises 1.1 Billion Yuan for Brain Chip

StairMed’s approach is different from Elon Musk’s Neuralink. Instead of requiring a robot to drill into the skull and place electrodes directly in brain tissue, the Chinese start-up says its device is delivered through a vein in the neck and travels through the blood vessels to the brain, much like a stent procedure. That could be a game changer if it works as advertised, because less invasive surgery generally means lower risk, shorter recovery times and, crucially, a wider patient pool.

For investors, the big takeaway is not that this will generate profits tomorrow. It is that China is building another potential battleground in advanced health tech, with government support and deep-pocketed sponsors willing to fund long development cycles. The global market for BCI implants is widely expected to become a multibillion-dollar industry, which helps explain why Tencent and Alibaba are willing to look past their rivalry and back the same platform.

There is still a long road ahead. StairMed has tested the technology only in sheep, not humans, so the leap from concept to clinic remains substantial. Synchron in the U.S. has already implanted devices in 10 patients across the U.S. and Australia since 2023, showing how much execution still matters in this field.

Still, this is the kind of early-stage technology investors may want to keep on the watchlist rather than dismiss. In the long run, the winners in BCI will likely be the companies that combine credible clinical data, manufacturing scale and regulatory approval. For now, Tencent and Alibaba’s backing tells you where part of China’s innovation capital is headed: toward a potentially historic intersection of AI, medical devices and human-machine interaction.